Globaler Markt für Diagnostik bei akuter myeloischer Leukämie – Branchentrends und Prognose bis 2031

Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

Globaler Markt für Diagnostik bei akuter myeloischer Leukämie – Branchentrends und Prognose bis 2031

  • Medical Devices
  • Publish Reports
  • Jan 2024
  • Global
  • 350 Seiten
  • Anzahl der Tabellen: 783
  • Anzahl der Abbildungen: 50

Global Acute Myeloid Leukemia Diagnostics Market

Marktgröße in Milliarden USD

CAGR :  % Diagram

Diagramm Prognosezeitraum
2024 –2031
Diagramm Marktgröße (Basisjahr)
USD 2,777.16 Million
Diagramm Marktgröße (Prognosejahr)
USD 6,538.78 Million
Diagramm CAGR
%
Diagramm Wichtige Marktteilnehmer
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Globaler Markt für Diagnostik bei akuter myeloischer Leukämie, nach Produkttyp (Instrumente, Verbrauchsmaterialien und Zubehör), Testtyp (Bildgebungstest, Bluttest, Knochenmarktest, Biomarkertest, Immunphänotypisierung, genetische Tests und andere), Krebsart (myeloblastisch (M0), myeloblastisch (M1), myeloblastisch (M2), promyelozytisch (M3), myelomonozytisch (M4), monozytisch (M5), Erythroleukämie (M6) und megakaryozytisch (M7)), Altersgruppe (65 und älter, unter 21, 21–29 und 30–65), Geschlecht (männlich und weiblich), Endbenutzer (Krankenhaus, verbundene Labore, unabhängige Diagnoselabore, Zentren für diagnostische Bildgebung, Krebsforschungsinstitute und andere), Vertriebskanal (direkte Ausschreibung und Einzelhandelsverkauf) – Branchentrends und Prognose bis 2031.

Markt für Diagnostik bei akuter myeloischer Leukämie

Marktanalyse und Einblicke in die Diagnostik akuter myeloischer Leukämie

Die weltweit zunehmende Verbreitung von Leukämiekrebs hat die Nachfrage nach Marktwachstum erhöht. Die steigenden Gesundheitsausgaben für bessere Gesundheitsdienste tragen ebenfalls zum Marktwachstum bei. Die wichtigsten Marktteilnehmer konzentrieren sich in dieser entscheidenden Zeit auf die Einführung und Zulassung verschiedener Dienste. Darüber hinaus trägt auch die Zunahme verbesserter Diagnoseverfahren und -techniken zur steigenden Nachfrage nach Blutkrebsdiagnostiktests bei. Es wird jedoch erwartet, dass eine späte Diagnose und eine schlechte Prognose von Leukämie das Marktwachstum im Prognosezeitraum behindern werden. Die steigenden Gesundheitsausgaben für Krebsdiagnose und -behandlung werden dem Markt voraussichtlich Möglichkeiten bieten, die Behandlung zu verbessern.

Markt für Diagnostik bei akuter myeloischer Leukämie

Markt für Diagnostik bei akuter myeloischer Leukämie

Der globale Markt für die Diagnostik akuter myeloischer Leukämie wird im Prognosezeitraum 2024 bis 2031 voraussichtlich wachsen. Laut einer Marktforschungsanalyse von Data Bridge wächst der Markt im Prognosezeitraum 2024 bis 2031 mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 11,3 % und dürfte von 2.777,16 Millionen USD im Jahr 2023 auf 6.538,78 Millionen USD im Jahr 2031 ansteigen.

Berichtsmetrik

Details

Prognosezeitraum

2024 bis 2031

Basisjahr

2023

Historisches Jahr

2022 (anpassbar für 2016–2021)

Quantitative Einheiten

Umsatz in Mio. USD

Abgedeckte Segmente

Produkttyp (Instrumente, Verbrauchsmaterialien und Zubehör), Testtyp (Bildgebungstest, Bluttest, Knochenmarkstest, Biomarkertest, Immunphänotypisierung, genetische Tests und andere), Krebsart (Myeloblastisch (M0), Myeloblastisch (M1), Myeloblastisch (M2), Promyelozytisch (M3), Myelomonozytisch (M4), Monozytisch (M5), Erythroleukämie (M6) und Megakaryozytisch (M7)), Altersgruppe (65 und älter, unter 21, 21–29 und 30–65), Geschlecht (männlich und weiblich), Endbenutzer (Krankenhaus, verbundene Labore, unabhängige Diagnoselabore, Zentren für diagnostische Bildgebung, Krebsforschungsinstitute und andere), Vertriebskanal (Direktausschreibung und Einzelhandelsverkauf)

Abgedeckte Länder

USA, Kanada, Mexiko, Deutschland, Großbritannien, Frankreich, Italien, Spanien, Russland, Niederlande, Schweiz, Belgien, Türkei, Restliches Europa, China, Japan, Indien, Australien, Südkorea, Indonesien, Philippinen, Thailand, Malaysia, Vietnam, Singapur, Restlicher Asien-Pazifik-Raum, Brasilien, Argentinien, Restliches Südamerika, Südafrika, Saudi-Arabien, Vereinigte Arabische Emirate, Ägypten, Israel und Restlicher Naher Osten und Afrika 

Abgedeckte Marktteilnehmer

CANON MEDICAL SYSTEMS CORPORATION, Sysmex Corporation, Epigenomics AG, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Abbott, QIAGEN, Agilent Technologies, Inc., Siemens Healthcare GmbH, BIOMERIEUX, Exact Sciences Corporation, Merck KGaA, Hologic Inc., DiaSorin SpA, Illumina, Inc., Koninklijke Philips NV, BD, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., FONAR Corp., Time Medical Holding., Sonic Healthcare, PlexBio, MinFound Medical Systems Co., Ltd, Medonica Co. Ltd, Thermo Fisher Scientific Inc. und SternMed GmbH, unter anderem

Marktdefinition

Akute myeloische Leukämie (AML) ist eine Krebserkrankung des Blutes und des Knochenmarks. Sie ist die häufigste Form akuter Leukämie bei Erwachsenen. Diese Krebsart verschlimmert sich in der Regel schnell, wenn sie nicht behandelt wird. AML wird auch als akute myeloische Leukämie und akute nichtlymphozytische Leukämie bezeichnet. Die meisten AML-Subtypen basieren darauf, wie reif (entwickelt) die Krebszellen zum Zeitpunkt der Diagnose sind und wie sehr sie sich von normalen Zellen unterscheiden.

Akute Promyelozytenleukämie (APL) ist ein Subtyp von AML. Diese Leukämie tritt auf, wenn Gene auf Chromosom 15 mit einigen Genen auf Chromosom 17 ihre Plätze tauschen und ein abnormales Gen namens PML-RARA gebildet wird. Das PML-RARA-Gen sendet eine Nachricht, die die Reifung von Promyelozyten (eine Art weißer Blutkörperchen) verhindert. Es können Probleme mit starken Blutungen und Blutgerinnseln auftreten. Dies ist ein ernstes Gesundheitsproblem, das so schnell wie möglich behandelt werden muss. APL tritt normalerweise bei Erwachsenen mittleren Alters auf.

Globale Marktdynamik für Diagnostik bei akuter myeloischer Leukämie

In diesem Abschnitt geht es um das Verständnis der Markttreiber, Beschränkungen, Chancen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:

Treiber

  • Wachsende Prävalenz von Leukämiekrebs

Leukämie kann in jedem Alter auftreten. Leukämie kann schwierig zu diagnostizieren sein, da sie trotz ihrer vielfältigen Anzeichen und Symptome unspezifisch ist und mit anderen, weiter verbreiteten Erkrankungen in Verbindung gebracht werden kann. AML ist eine der vier häufigsten Leukämiearten bei Erwachsenen. Sie tritt seltener auf. Männer sind etwas häufiger betroffen als Frauen. Das durchschnittliche Lebenszeitrisiko, an AML zu erkranken, beträgt bei beiden Geschlechtern jedoch durchschnittlich etwa ½ von 1 %.

AML ist die zweithäufigste Leukämieart, die bei Erwachsenen und Kindern diagnostiziert wird, die meisten Fälle treten jedoch bei Erwachsenen auf. Obwohl die Krankheit in jedem Alter diagnostiziert werden kann, ist sie vor dem 45. Lebensjahr selten. Das durchschnittliche Diagnosealter liegt bei 68 Jahren. Die steigenden Raten an Fettleibigkeit bei Müttern könnten teilweise für den Anstieg der AML-Prävalenz verantwortlich sein.

Aufgrund verschiedener Risikofaktoren nimmt die Anzahl der Fälle von AML zu und stellt ein erhebliches sozioökonomisches Problem dar. Dies dürfte das Marktwachstum ankurbeln.

  • Neue technologische Fortschritte in der Leukämiediagnostik

Die häufigste Form von Blutkrebs, AML, ist zugleich eine der seltenen Formen von Leukämie. Diese Krebsform befällt das Blut und breitet sich dann auf nahegelegene Organe und Körpersysteme aus. Spezialisten müssen Krebszellen und nicht krebsartige Zellen manuell diagnostizieren, indem sie Zellbilder unter einem Mikroskop untersuchen und Beschriftungen durch Anmerkungen anbringen. Diese manuelle mikroskopische Untersuchung ist jedoch zeitaufwändig und kann zu einer falschen Diagnose führen.

Das Risiko, falsche Medikamente zu verschreiben, wurde mithilfe computergestützter Software verringert. Die Entwicklung eines automatischen und zuverlässigen Klassifizierungssystems wurde unerlässlich, um die verheerenden Auswirkungen der Leukämie einzudämmen. Mehrere Segmentierungstechniken bildeten die Grundlage der bestehenden Leukämie-Klassifizierungsalgorithmen.

Die Entwicklung mehrerer neuer Diagnosemethoden wird das Marktwachstum steigern, da viele neue und fortschrittliche Produkte auf den Markt kommen. Daher wird erwartet, dass auf dem Markt eine Nachfrage nach Diagnoseprodukten für akuten Leukämiekrebs entsteht.

  • Steigendes Bewusstsein für Leukämiekrebs

Die Aufklärung über akute Leukämie ist eine Chance, das Wissen über diese Krankheiten zu erweitern und die Erforschung ihrer Ursachen, Prävention, Diagnose, Behandlung und Überlebenschancen in den Mittelpunkt zu rücken. Ziel ist es, Menschen zu helfen, die von Leukämie betroffen sind, und gesunde Gewohnheiten zu fördern.

Jedes Jahr sind mehrere Aufklärungskampagnen geplant, um die Menschen über Leukämie aufzuklären. Verschiedene Organisationen übernehmen dabei die Führung. Infolgedessen wird erwartet, dass dies das Marktwachstum vorantreibt.

Markt für Diagnostik bei akuter myeloischer Leukämie

Gelegenheit

  • Zunahme bei Diagnoseprodukten für Leukämie

Die Zunahme an speziell für Leukämie entwickelten Diagnoseprodukten stellt eine bemerkenswerte Chance für den Gesundheitssektor dar. Diese Expansion bedeutet einen wachsenden Fokus auf maßgeschneiderte Diagnoselösungen, die genauere und umfassendere Methoden zur Identifizierung verschiedener Subtypen und Stadien von Leukämie bieten. Diese Fortschritte ermöglichen frühere und präzisere Diagnosen und ermöglichen es Gesundheitsdienstleistern, umgehende und gezielte Behandlungsstrategien einzuleiten. Darüber hinaus schafft die sich entwickelnde Landschaft der Diagnoseprodukte Möglichkeiten für Innovationen und fördert die Entwicklung neuer Technologien und Ansätze, die die allgemeine Behandlung und Prognose von Leukämiepatienten weiter verbessern können.

Einschränkungen/Herausforderungen

  • Strenge Vorschriften und Standards für die Zulassung und Vermarktung von Leukämiediagnostikprodukten

Die strengen Bestimmungen für die Vermarktung aller Produkte erweisen sich als große Herausforderung für die Hersteller von Krebsdiagnostikprodukten, für die es Vorschriften und ein eigenes Gremium für die Zulassungsverfahren gibt.

Hersteller müssen zunächst die CE-Kennzeichnung prüfen, bevor ihr Produkt auf den Markt kommt. Die strengen Regulierungsrichtlinien dürften das Wachstum und die Entwicklung des Marktes behindern.

  • Späte Diagnose und schlechte Prognose bei Leukämie

Krebs ist die häufigste Todesursache in Nordamerika. Bei frühzeitiger Diagnose und richtiger Behandlung können einige Krebsarten jedoch geheilt werden. Im Diagnoseprozess kann es zu Verzögerungen bei der Krebsdiagnose kommen. Wenn Patienten potenzielle Krebssymptome übersehen oder nicht darauf reagieren, verzögert sich die Diagnose. Der Hauptgrund für die verzögerte Diagnose ist die mangelnde Kenntnis der Öffentlichkeit über frühe Krebssymptome, insbesondere wenn diese ungewöhnlich sind.

Diese Faktoren führen häufig zu einer späten Diagnose und damit zu einer schlechten Prognose. Daher ist zu erwarten, dass diese Faktoren das Marktwachstum bremsen.

  • Erhöhte Kosten, Sicherheit und Komfortprobleme

Leukämie ist eine tödliche Krebserkrankung, und der Diagnoseprozess ist zudem mit Sicherheitsproblemen verbunden. Er ist nicht kosteneffizient. Krebs ist eine der teuersten Erkrankungen. Krebspatienten müssen ins Krankenhaus und erhalten verschiedene Therapien, wie z. B. Operationen, Strahlentherapie und systemische Therapie. Die Krankenversicherungsbeiträge für Krebspatienten sind heute höher als früher. Darüber hinaus steigen ihre Zuzahlungs-, Selbstbehalts- und Zuzahlungskosten.

Daher sind mit dem aktuellen Verfahren zur Leukämiediagnose Probleme hinsichtlich Sicherheit, Kosten und Benutzerfreundlichkeit verbunden, die voraussichtlich eine Herausforderung für das Marktwachstum darstellen werden.

Jüngste Entwicklung

  • Im November 2022 übernahm Canon Inc. Redlen Technologies Inc. (Redlen), eines der weltweit führenden Unternehmen für die Entwicklung neuer Technologien im Zusammenhang mit der Entwicklung und Herstellung von Halbleiterdetektormodulen. Canon Medical Systems Corporation (Canon Medical), ein Konzernunternehmen von Canon Inc., hat das erste im Inland produzierte Photon-Counting CT (PCCT)-System entwickelt, das die fortschrittlichen Technologien von Redlen enthält. Dieses System wurde im Exploratory Oncology Research & Clinical Trial Center des National Cancer Center (NCC) in Japan installiert, wo es derzeit zur Erforschung der klinischen Anwendungen von PCCT verwendet wird.

Globaler Markt für Diagnostik bei akuter myeloischer Leukämie

Der globale Markt für Diagnostik bei akuter myeloischer Leukämie ist in sieben wichtige Segmente unterteilt, basierend auf Produkttyp, Testtyp, Krebsart, Altersgruppe, Geschlecht, Endbenutzer und Vertriebskanal. Das Wachstum dieser Segmente hilft Ihnen bei der Analyse wichtiger Wachstumssegmente in den Branchen und bietet den Benutzern einen wertvollen Marktüberblick und Markteinblicke, um strategische Entscheidungen zur Identifizierung der wichtigsten Marktanwendungen zu treffen.

Produkttyp

  • Instrumente
  • Verbrauchsmaterial und Zubehör

Basierend auf dem Produkttyp ist der Markt in Instrumente sowie Verbrauchsmaterialien und Zubehör segmentiert.

 Testtyp

  • Blutprobe
  • Bildgebungstest
  • Knochenmarksuntersuchung
  • Genetische Tests
  • Biomarker-Test
  • Immunphänotypisierung
  • Sonstiges

Basierend auf dem Testtyp ist der Markt in Bluttests, bildgebende Tests, Knochenmarktests, genetische Tests, Biomarkertests, Immunphänotypisierung und andere unterteilt.

Krebsart

  • Myeloblastisch (M0)
  • Myeloblastisch (M1)
  • Myeloblastisch (M2)
  • Promyelozyten (M3)
  • Myelomonozytär (M4)
  • Monozytär (M5)
  • Erythroleukämie (M6)
  • Megakaryozyten (M7)

Basierend auf der Krebsart ist der Markt in myeloblastische (M0), myeloblastische (M1), myeloblastische (M2), promyelozytische (M3), myelomonozytische (M4), monozytische (M5), Erythroleukämie (M6) und megakaryozytische (M7) unterteilt.

Altersgruppe

  • Unter 21
  • 21-29
  • 30-65
  • 65 und älter

Basierend auf den Altersgruppen ist der Markt in unter 21, 21–29, 30–65 und 65 und älter segmentiert.

Geschlecht

  •  Männlich
  •  Weiblich

Basierend auf dem Geschlecht ist der Markt in männlich und weiblich segmentiert.

Endbenutzer

  • Krankenhaus
  • Zugehörige Labore
  • Unabhängige Diagnoselabore
  • Zentren für diagnostische Bildgebung
  • Krebsforschungsinstitute
  • Sonstiges

Basierend auf dem Endbenutzer ist der Markt in Krankenhäuser, zugehörige Labore, unabhängige Diagnoselabore, Zentren für diagnostische Bildgebung, Krebsforschungsinstitute und andere segmentiert.

Vertriebskanal

  • Direkte Ausschreibung
  • Einzelhandelsumsätze

Basierend auf dem Vertriebskanal ist der Markt in Direktausschreibung und Einzelhandelsverkauf segmentiert.

Markt für Diagnostik bei akuter myeloischer Leukämie

Globaler Markt für Diagnostik bei akuter myeloischer Leukämie – Regionale Analyse/Einblicke      

Der globale Markt für die Diagnostik akuter myeloischer Leukämie wird analysiert und es werden Erkenntnisse und Trends zur Marktgröße nach Ländern basierend auf Produkttyp, Testtyp, Krebsart, Altersgruppe, Geschlecht, Endbenutzer und Vertriebskanal bereitgestellt.

Die in diesem Marktbericht abgedeckten Länder sind die USA, Kanada, Mexiko, Deutschland, Großbritannien, Frankreich, Italien, Spanien, Russland, Niederlande, Schweiz, Belgien, Türkei, übriges Europa, China, Japan, Indien, Australien, Südkorea, Indonesien, Philippinen, Thailand, Malaysia, Vietnam, Singapur, übriger asiatisch-pazifischer Raum, Brasilien, Argentinien, übriges Südamerika, Südafrika, Saudi-Arabien, Vereinigte Arabische Emirate, Ägypten, Israel und der restliche Nahe Osten und Afrika, wie oben angegeben.

Nordamerika dominiert den globalen Markt für die Diagnostik akuter myeloischer Leukämie aufgrund neuer technologischer Fortschritte in der Leukämiediagnostik. Die USA dominieren den nordamerikanischen Markt für die Diagnostik akuter myeloischer Leukämie aufgrund der zunehmenden Präferenz für Vorsorgeuntersuchungen. Deutschland dominiert den europäischen Markt für die Diagnostik akuter myeloischer Leukämie aufgrund der zunehmenden technologischen Fortschritte, der Verwendung von Instrumenten und Verbrauchsmaterialien für die Diagnostik in der Region. China dominiert den Markt für die Diagnostik akuter myeloischer Leukämie im asiatisch-pazifischen Raum aufgrund wachsender Investitionen in Forschung und Entwicklung sowie der Einführung neuer Produkte, die das Marktwachstum ankurbeln.

Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Regulierungen auf dem Markt, die sich auf die aktuellen und zukünftigen Trends des Marktes auswirken. Datenpunkte wie Neu- und Ersatzverkäufe, Länderdemografie, Krankheitsepidemiologie und Import- und Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Darüber hinaus werden bei der Prognoseanalyse der Länderdaten die Präsenz und Verfügbarkeit globaler Marken und ihre Herausforderungen aufgrund der Konkurrenz durch lokale und globale Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.

Markt für Diagnostik bei akuter myeloischer Leukämie

Wettbewerbsumfeld und globale Analyse der Marktanteile für Diagnostik bei akuter myeloischer Leukämie

Die Wettbewerbslandschaft des globalen Marktes für Diagnostik bei akuter myeloischer Leukämie liefert Details nach Wettbewerbern. Die enthaltenen Details sind Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, globale Präsenz, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen in Bezug auf den Markt.

Zu den wichtigsten Akteuren auf dem globalen Markt für die Diagnostik akuter myeloischer Leukämie zählen unter anderem CANON MEDICAL SYSTEMS CORPORATION, Sysmex Corporation, Epigenomics AG, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Abbott, QIAGEN, Agilent Technologies, Inc., Siemens Healthcare GmbH, BIOMERIEUX, Exact Sciences Corporation, Merck KGaA, Hologic Inc., DiaSorin SpA, Illumina, Inc., Koninklijke Philips NV, BD, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., FONAR Corp., Time Medical Holding., Sonic Healthcare, PlexBio, MinFound Medical Systems Co., Ltd, Medonica Co. Ltd, Thermo Fisher Scientific Inc. und SternMed GmbH.


SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 EPIDEMIOLOGY

5 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS

5.1 REGULATORY SCENARIO IN THE U.S.

5.2 REGULATORY SCENARIO IN AUSTRALIA

5.3 REGULATORY SCENARIO IN JAPAN

5.4 REGULATORY SCENARIO IN CHINA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER

6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS

6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS

6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER

6.2 RESTRAINTS

6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS

6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA

6.3 OPPORTUNITIES

6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA

6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT

6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS

6.4 CHALLENGES

6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES

6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS

7 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 INSTRUMENTS

7.2.1 BIOPSY INSTRUMENTS

7.2.1.1 BONE MARROW BIOPSY

7.2.1.2 NEEDLE BIOPSY

7.2.1.3 SURGICAL BIOPSY

7.2.1.4 OTHERS

7.2.2 PATHOLOGY-BASED INSTRUMENTS

7.2.2.1 PCR INSTRUMENTS

7.2.2.2 SLIDE STAINING SYSTEMS

7.2.2.3 TISSUE PROCESSING SYSTEMS

7.2.2.4 CELL PROCESSORS

7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS

7.2.3 IMAGING INSTRUMENTS

7.2.3.1 ULTRASOUND SYSTEMS

7.2.3.2 CT SYSTEMS

7.2.3.3 MRI SYSTEMS

7.2.3.4 OTHERS

7.2.4 OTHERS

7.3 CONSUMABLES & ACCESSORIES

7.3.1 KITS

7.3.1.1 PCR KITS

7.3.1.2 DNA POLYMERASE KITS

7.3.1.3 NUCLEIC ACID ISOLATION KITS

7.3.1.4 OTHERS

7.3.2 REAGENTS

7.3.2.1 ASSAYS

7.3.2.2 BUFFERS

7.3.2.3 PRIMERS

7.3.2.4 OTHERS

7.3.3 PROBES

7.3.4 OTHER CONSUMABLES

8 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 BLOOD TEST

8.2.1 COMPLETE BLOOD COUNT (CBC)

8.2.2 BLOOD CHEMISTRY TESTS

8.2.3 OTHERS

8.3 IMAGING TEST

8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN

8.3.2 MRI

8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN

8.3.4 OTHERS

8.4 BONE MARROW TESTS

8.4.1 BONE MARROW ASPIRATE

8.4.2 BONE MARROW BIOPSY

8.4.3 OTHERS

8.5 GENETIC TESTS

8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)

8.5.2 KARYOTYPING

8.5.3 OTHERS

8.6 BIOMARKER TEST

8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER

8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER

8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER

8.7 IMMUNOPHENOTYPING

8.7.1 FLOW CYTOMETRY

8.7.2 IMMUNOHISTOCHEMISTRY

8.7.3 OTHERS

8.8 OTHERS

9 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE

9.1 OVERVIEW

9.2 MYELOBLASTIC (M0)

9.3 MYELOBLASTIC (M1)

9.4 MYELOBLASTIC (M2)

9.5 PROMYELOCYTIC (M3)

9.6 MYELOMONOCYTIC (M4)

9.7 MONOCYTIC (M5)

9.8 ERYTHROLEUKEMIA (M6)

9.9 MEGAKARYOCYTIC (M7)

10 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP

10.1 OVERVIEW

10.2 65 AND ABOVE

10.3 30-65

10.4 BELOW 21

10.5 21-29

11 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER

11.1 OVERVIEW

11.2 MALE

11.3 FEMALE

12 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.3 ASSOCIATED LABS

12.4 INDEPENDENT DIAGNOSTIC LABORATORIES

12.5 DIAGNOSTIC IMAGING CENTERS

12.6 CANCER RESEARCH INSTITUTES

12.7 OTHERS

13 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAIL SALES

14 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION

14.1 OVERVIEW

14.2 NORTH AMERICA

14.2.1 U.S.

14.2.2 CANADA

14.2.3 MEXICO

14.3 EUROPE

14.3.1 GERMANY

14.3.2 UNITED KINGDOM

14.3.3 FRANCE

14.3.4 ITALY

14.3.5 SPAIN

14.3.6 RUSSIA

14.3.7 NETHERLANDS

14.3.8 SWITZERLAND

14.3.9 BELGIUM

14.3.10 TURKEY

14.3.11 REST OF EUROPE

14.4 ASIA-PACIFIC

14.4.1 CHINA

14.4.2 JAPAN

14.4.3 INDIA

14.4.4 AUSTRALIA

14.4.5 SOUTH KOREA

14.4.6 INDONESIA

14.4.7 PHILIPPINES

14.4.8 THAILAND

14.4.9 MALAYSIA

14.4.10 VIETNAM

14.4.11 SINGAPORE

14.4.12 REST OF ASIA-PACIFIC

14.5 SOUTH AMERICA

14.5.1 BRAZIL

14.5.2 ARGENTINA

14.5.3 REST OF SOUTH AMERICA

14.6 MIDDLE EAST AND AFRICA

14.6.1 SOUTH AFRICA

14.6.2 SAUDI ARABIA

14.6.3 U.A.E

14.6.4 EGYPT

14.6.5 ISRAEL

14.6.6 REST OF MIDDLE EAST AND AFRICA

15 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: GLOBAL

15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

15.3 COMPANY SHARE ANALYSIS: EUROPE

15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 CANON MEDICAL SYSTEMS CORPORATION.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 SYSMEX CORPORATION

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 EPIGENOMICS AG.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 MYRIAD GENETICS, INC.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 F. HOFFMANN- LA ROCHE LTD

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 ABBOTT

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.7 AGILENT TECHNOLOGIES, INC.

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 BD

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENT

17.9 BIOMERIEUX

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.1 BIO-RAD LABORATORIES, INC.

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.11 DIASORIN S.P.A.

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENTS

17.12 EXACT SCIENCES CORPORATION

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENTS

17.13 HOLOGIC INC.

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 ILLUMINA, INC.

17.14.1 COMPANY SNAPSHOT

17.14.2 REVENUE ANALYSIS

17.14.3 PRODUCT PORTFOLIO

17.14.4 RECENT DEVELOPMENT

17.15 KONINKLIJKE PHILIPS N.V.

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENT

17.16 MEDONICA CO. LTD

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.17 MINFOUND MEDICAL SYSTEMS CO., LTD

17.17.1 COMPANY SNAPSHOT

17.17.2 PRODUCT PORTFOLIO

17.17.3 RECENT DEVELOPMENT

17.18 PLEXBIO

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT DEVELOPMENTS

17.19 QIAGEN

17.19.1 COMPANY SNAPSHOT

17.19.2 REVENUE ANALYSIS

17.19.3 PRODUCT PORTFOLIO

17.19.4 RECENT DEVELOPMENTS

17.2 QUEST DIAGNOSTICS INCORPORATED

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENTS

17.21 SIEMENS HEALTHCARE GMBH

17.21.1 COMPANY SNAPSHOT

17.21.2 REVENUE ANALYSIS

17.21.3 PRODUCT PORTFOLIO

17.21.4 RECENT DEVELOPMENT

17.22 SONIC HEALTHCARE

17.22.1 COMPANY SNAPSHOT

17.22.2 PRODUCT PORTFOLIO

17.22.3 RECENT DEVELOPMENT

17.23 STERNMED GMBH

17.23.1 COMPANY SNAPSHOT

17.23.2 PRODUCT PORTFOLIO

17.23.3 RECENT DEVELOPMENTS

17.24 THERMO FISHER SCIENTIFIC INC.

17.24.1 COMPANY SNAPSHOT

17.24.2 REVENUE ANALYSIS

17.24.3 PRODUCT PORTFOLIO

17.24.4 RECENT DEVELOPMENT

17.25 TIME MEDICAL HOLDING

17.25.1 COMPANY SNAPSHOT

17.25.2 PRODUCT PORTFOLIO

17.25.3 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA

TABLE 2 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 3 GLOBAL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 4 GLOBAL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 5 GLOBAL BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 13 GLOBAL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 14 GLOBAL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 17 GLOBAL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 18 GLOBAL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 19 GLOBAL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 20 GLOBAL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 21 GLOBAL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 22 GLOBAL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 23 GLOBAL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 24 GLOBAL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 25 GLOBAL OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 26 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 27 GLOBAL MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 28 GLOBAL MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 29 GLOBAL MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 30 GLOBAL PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 31 GLOBAL MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 32 GLOBAL MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 33 GLOBAL ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 GLOBAL MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 35 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 36 GLOBAL 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 37 GLOBAL 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 38 GLOBAL BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 39 GLOBAL 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 40 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 41 GLOBAL MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 42 GLOBAL FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 43 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 44 GLOBAL HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 45 GLOBAL ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 46 GLOBAL INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 47 GLOBAL DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 48 GLOBAL CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 49 GLOBAL OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 50 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 51 GLOBAL DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 52 GLOBAL RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 53 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 54 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 55 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 56 NORTH AMERICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 57 NORTH AMERICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 58 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 59 NORTH AMERICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 60 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 61 NORTH AMERICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 62 NORTH AMERICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 63 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 64 NORTH AMERICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 65 NORTH AMERICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 66 NORTH AMERICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 67 NORTH AMERICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 68 NORTH AMERICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 69 NORTH AMERICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 70 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 71 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 72 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 73 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 74 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 75 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 76 U.S. INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 77 U.S. BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 78 U.S. PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 79 U.S. IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 80 U.S. CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 81 U.S. KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 82 U.S. REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 83 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 84 U.S. BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 85 U.S. IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 86 U.S. BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 87 U.S. GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 88 U.S. BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 89 U.S. IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 90 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 91 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 92 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 93 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 94 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 95 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 96 CANADA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 97 CANADA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 98 CANADA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 99 CANADA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 100 CANADA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 101 CANADA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 102 CANADA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 103 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 104 CANADA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 105 CANADA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 106 CANADA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 107 CANADA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 108 CANADA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 109 CANADA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 110 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 111 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 112 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 113 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 114 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 115 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 116 MEXICO INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 117 MEXICO BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 118 MEXICO PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 119 MEXICO IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 120 MEXICO CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 121 MEXICO KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 122 MEXICO REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 123 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 124 MEXICO BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 125 MEXICO IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 126 MEXICO BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 127 MEXICO GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 128 MEXICO BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 129 MEXICO IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 130 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 131 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 132 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 133 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 134 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 135 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 136 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 137 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 138 EUROPE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 139 EUROPE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 140 EUROPE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 141 EUROPE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 142 EUROPE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 143 EUROPE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 144 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 145 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 146 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 147 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 148 EUROPE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 149 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 150 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 151 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 152 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 153 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 154 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 155 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 156 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 157 GERMANY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 158 GERMANY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 159 GERMANY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 160 GERMANY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 161 GERMANY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 162 GERMANY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 163 GERMANY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 164 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 165 GERMANY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 166 GERMANY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 167 GERMANY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 168 GERMANY GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 169 GERMANY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 170 GERMANY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 171 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 172 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 173 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 174 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 175 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 176 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 177 UNITED KINGDOM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 178 UNITED KINGDOM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 179 UNITED KINGDOM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 180 UNITED KINGDOM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 181 UNITED KINGDOM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 182 UNITED KINGDOM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 183 UNITED KINGDOM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 184 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 185 UNITED KINGDOM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 186 UNITED KINGDOM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 187 UNITED KINGDOM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 188 UNITED KINGDOM GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 189 UNITED KINGDOM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 190 UNITED KINGDOM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 191 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 192 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 193 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 194 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 195 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 196 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 197 FRANCE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 198 FRANCE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 199 FRANCE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 200 FRANCE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 201 FRANCE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 202 FRANCE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 203 FRANCE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 204 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 205 FRANCE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 206 FRANCE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 207 FRANCE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 208 FRANCE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 209 FRANCE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 210 FRANCE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 211 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 212 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 213 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 214 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 215 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 216 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 217 ITALY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 218 ITALY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 219 ITALY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 220 ITALY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 221 ITALY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 222 ITALY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 223 ITALY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 224 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 225 ITALY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 226 ITALY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 227 ITALY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 228 ITALY GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 229 ITALY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 230 ITALY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 231 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 232 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 233 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 234 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 235 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 236 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 237 SPAIN INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 238 SPAIN BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 239 SPAIN PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 240 SPAIN IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 241 SPAIN CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 242 SPAIN KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 243 SPAIN REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 244 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 245 SPAIN BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 246 SPAIN IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 247 SPAIN BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 248 SPAIN GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 249 SPAIN BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 250 SPAIN IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 251 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 252 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 253 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 254 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 255 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 256 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 257 RUSSIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 258 RUSSIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 259 RUSSIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 260 RUSSIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 261 RUSSIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 262 RUSSIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 263 RUSSIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 264 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 265 RUSSIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 266 RUSSIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 267 RUSSIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 268 RUSSIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 269 RUSSIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 270 RUSSIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 271 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 272 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 273 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 274 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 275 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 276 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 277 NETHERLANDS INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 278 NETHERLANDS BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 279 NETHERLANDS PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 280 NETHERLANDS IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 281 NETHERLANDS CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 282 NETHERLANDS KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 283 NETHERLANDS REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 284 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 285 NETHERLANDS BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 286 NETHERLANDS IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 287 NETHERLANDS BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 288 NETHERLANDS GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 289 NETHERLANDS BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 290 NETHERLANDS IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 291 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 292 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 293 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 294 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 295 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 296 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 297 SWITZERLAND INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 298 SWITZERLAND BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 299 SWITZERLAND PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 300 SWITZERLAND IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 301 SWITZERLAND CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 302 SWITZERLAND KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 303 SWITZERLAND REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 304 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 305 SWITZERLAND BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 306 SWITZERLAND IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 307 SWITZERLAND BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 308 SWITZERLAND GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 309 SWITZERLAND BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 310 SWITZERLAND IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 311 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 312 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 313 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 314 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 315 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 316 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 317 BELGIUM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 318 BELGIUM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 319 BELGIUM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 320 BELGIUM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 321 BELGIUM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 322 BELGIUM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 323 BELGIUM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 324 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 325 BELGIUM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 326 BELGIUM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 327 BELGIUM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 328 BELGIUM GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 329 BELGIUM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 330 BELGIUM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 331 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 332 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 333 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 334 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 335 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 336 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 337 TURKEY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 338 TURKEY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 339 TURKEY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 340 TURKEY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 341 TURKEY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 342 TURKEY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 343 TURKEY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 344 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 345 TURKEY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 346 TURKEY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 347 TURKEY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 348 TURKEY GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 349 TURKEY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 350 TURKEY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 351 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 352 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 353 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 354 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 355 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 356 REST OF EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 357 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 358 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 359 ASIA-PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 360 ASIA-PACIFIC BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 361 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 362 ASIA-PACIFIC IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 363 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 364 ASIA-PACIFIC KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 365 ASIA-PACIFIC REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 366 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 367 ASIA-PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 368 ASIA-PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 369 ASIA-PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 370 ASIA-PACIFIC GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 371 ASIA-PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 372 ASIA-PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 373 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 374 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 375 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 376 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 377 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 378 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 379 CHINA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 380 CHINA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 381 CHINA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 382 CHINA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 383 CHINA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 384 CHINA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 385 CHINA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 386 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 387 CHINA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 388 CHINA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 389 CHINA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 390 CHINA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 391 CHINA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 392 CHINA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 393 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 394 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 395 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 396 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 397 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 398 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 399 JAPAN INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 400 JAPAN BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 401 JAPAN PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 402 JAPAN IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 403 JAPAN CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 404 JAPAN KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 405 JAPAN REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 406 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 407 JAPAN BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 408 JAPAN IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 409 JAPAN BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 410 JAPAN GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 411 JAPAN BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 412 JAPAN IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 413 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 414 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 415 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 416 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 417 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 418 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 419 INDIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 420 INDIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 421 INDIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 422 INDIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 423 INDIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 424 INDIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 425 INDIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 426 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 427 INDIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 428 INDIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 429 INDIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 430 INDIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 431 INDIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 432 INDIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 433 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 434 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 435 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 436 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 437 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 438 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 439 AUSTRALIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 440 AUSTRALIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 441 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 442 AUSTRALIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 443 AUSTRALIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 444 AUSTRALIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 445 AUSTRALIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 446 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 447 AUSTRALIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 448 AUSTRALIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 449 AUSTRALIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 450 AUSTRALIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 451 AUSTRALIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 452 AUSTRALIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 453 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 454 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 455 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 456 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 457 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 458 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 459 SOUTH KOREA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 460 SOUTH KOREA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 461 SOUTH KOREA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 462 SOUTH KOREA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 463 SOUTH KOREA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 464 SOUTH KOREA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 465 SOUTH KOREA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 466 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 467 SOUTH KOREA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 468 SOUTH KOREA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 469 SOUTH KOREA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 470 SOUTH KOREA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 471 SOUTH KOREA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 472 SOUTH KOREA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 473 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 474 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 475 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 476 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 477 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 478 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 479 INDONESIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 480 INDONESIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 481 INDONESIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 482 INDONESIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 483 INDONESIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 484 INDONESIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 485 INDONESIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 486 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 487 INDONESIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 488 INDONESIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 489 INDONESIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 490 INDONESIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 491 INDONESIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 492 INDONESIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 493 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 494 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 495 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 496 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 497 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 498 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 499 PHILIPPINES INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 500 PHILIPPINES BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 501 PHILIPPINES PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 502 PHILIPPINES IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 503 PHILIPPINES CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 504 PHILIPPINES KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 505 PHILIPPINES REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 506 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 507 PHILIPPINES BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 508 PHILIPPINES IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 509 PHILIPPINES BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 510 PHILIPPINES GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 511 PHILIPPINES BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 512 PHILIPPINES IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 513 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 514 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 515 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 516 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 517 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 518 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 519 THAILAND INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 520 THAILAND BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 521 THAILAND PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 522 THAILAND IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 523 THAILAND CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 524 THAILAND KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 525 THAILAND REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 526 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 527 THAILAND BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 528 THAILAND IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 529 THAILAND BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 530 THAILAND GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 531 THAILAND BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 532 THAILAND IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 533 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 534 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 535 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 536 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 537 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 538 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 539 MALAYSIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 540 MALAYSIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 541 MALAYSIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 542 MALAYSIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 543 MALAYSIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 544 MALAYSIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 545 MALAYSIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 546 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 547 MALAYSIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 548 MALAYSIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 549 MALAYSIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 550 MALAYSIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 551 MALAYSIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 552 MALAYSIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 553 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 554 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 555 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 556 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 557 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 558 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 559 VIETNAM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 560 VIETNAM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 561 VIETNAM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 562 VIETNAM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 563 VIETNAM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 564 VIETNAM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 565 VIETNAM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 566 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 567 VIETNAM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 568 VIETNAM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 569 VIETNAM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 570 VIETNAM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 571 VIETNAM GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 572 VIETNAM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 573 VIETNAM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 574 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 575 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 576 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 577 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 578 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 579 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 580 SINGAPORE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 581 SINGAPORE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 582 SINGAPORE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 583 SINGAPORE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 584 SINGAPORE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 585 SINGAPORE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 586 SINGAPORE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 587 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 588 SINGAPORE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 589 SINGAPORE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 590 SINGAPORE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 591 SINGAPORE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 592 SINGAPORE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 593 SINGAPORE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 594 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 595 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 596 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 597 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 598 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 599 REST OF ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 600 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 601 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 602 SOUTH AMERICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 603 SOUTH AMERICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 604 SOUTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 605 SOUTH AMERICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 606 SOUTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 607 SOUTH AMERICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 608 SOUTH AMERICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 609 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 610 SOUTH AMERICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 611 SOUTH AMERICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 612 SOUTH AMERICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 613 SOUTH AMERICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 614 SOUTH AMERICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 615 SOUTH AMERICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 616 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 617 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 618 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 619 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 620 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 621 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 622 BRAZIL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 623 BRAZIL BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 624 BRAZIL PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 625 BRAZIL IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 626 BRAZIL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 627 BRAZIL KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 628 BRAZIL REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 629 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 630 BRAZIL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 631 BRAZIL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 632 BRAZIL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 633 BRAZIL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 634 BRAZIL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 635 BRAZIL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 636 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 637 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 638 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 639 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 640 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 641 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 642 ARGENTINA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 643 ARGENTINA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 644 ARGENTINA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 645 ARGENTINA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 646 ARGENTINA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 647 ARGENTINA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 648 ARGENTINA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 649 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 650 ARGENTINA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 651 ARGENTINA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 652 ARGENTINA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 653 ARGENTINA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 654 ARGENTINA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 655 ARGENTINA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 656 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 657 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 658 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 659 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 660 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 661 REST OF SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 662 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 663 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 664 MIDDLE EAST AND AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 665 MIDDLE EAST AND AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 666 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 667 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 668 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 669 MIDDLE EAST AND AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 670 MIDDLE EAST AND AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 671 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 672 MIDDLE EAST AND AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 673 MIDDLE EAST AND AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 674 MIDDLE EAST AND AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 675 MIDDLE EAST AND AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 676 MIDDLE EAST AND AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 677 MIDDLE EAST AND AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 678 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 679 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 680 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 681 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 682 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 683 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 684 SOUTH AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 685 SOUTH AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 686 SOUTH AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 687 SOUTH AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 688 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 689 SOUTH AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 690 SOUTH AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 691 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 692 SOUTH AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 693 SOUTH AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 694 SOUTH AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 695 SOUTH AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 696 SOUTH AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 697 SOUTH AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 698 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 699 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 700 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 701 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 702 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 703 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 704 SAUDI ARABIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 705 SAUDI ARABIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 706 SAUDI ARABIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 707 SAUDI ARABIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 708 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 709 SAUDI ARABIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 710 SAUDI ARABIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 711 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 712 SAUDI ARABIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 713 SAUDI ARABIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 714 SAUDI ARABIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 715 SAUDI ARABIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 716 SAUDI ARABIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 717 SAUDI ARABIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 718 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 719 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 720 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 721 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 722 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 723 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 724 U.A.E. INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 725 U.A.E. BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 726 U.A.E. PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 727 U.A.E. IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 728 U.A.E. CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 729 U.A.E. KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 730 U.A.E. REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 731 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 732 U.A.E. BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 733 U.A.E. IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 734 U.A.E. BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 735 U.A.E. GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 736 U.A.E. BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 737 U.A.E. IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 738 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 739 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 740 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 741 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 742 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 743 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 744 EGYPT INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 745 EGYPT BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 746 EGYPT PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 747 EGYPT IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 748 EGYPT CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 749 EGYPT KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 750 EGYPT REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 751 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 752 EGYPT BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 753 EGYPT IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 754 EGYPT BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 755 EGYPT GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 756 EGYPT BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 757 EGYPT IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 758 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 759 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 760 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 761 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 762 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 763 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 764 ISRAEL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 765 ISRAEL BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 766 ISRAEL PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 767 ISRAEL IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 768 ISRAEL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 769 ISRAEL KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 770 ISRAEL REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 771 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 772 ISRAEL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 773 ISRAEL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 774 ISRAEL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 775 ISRAEL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 776 ISRAEL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 777 ISRAEL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 778 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 779 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 780 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 781 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 782 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 783 REST OF MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

Abbildungsverzeichnis

FIGURE 1 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD

FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2024 & 2031

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET

FIGURE 16 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES)

FIGURE 17 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES)

FIGURE 18 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023

FIGURE 19 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)

FIGURE 20 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2024-2031)

FIGURE 21 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 22 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023

FIGURE 23 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2024-2031 (USD MILLION)

FIGURE 24 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2024-2031)

FIGURE 25 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 26 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023

FIGURE 27 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2024-2031 (USD MILLION)

FIGURE 28 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2024-2031)

FIGURE 29 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 30 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023

FIGURE 31 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION)

FIGURE 32 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2024-2031)

FIGURE 33 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 34 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023

FIGURE 35 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2024-2031 (USD MILLION)

FIGURE 36 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 37 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 38 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023

FIGURE 39 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2024-2031 (USD MILLION)

FIGURE 40 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2024-2031)

FIGURE 41 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 42 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 43 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 44 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 45 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 46 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2023)

FIGURE 47 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2023(%)

FIGURE 48 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)

FIGURE 49 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)

FIGURE 50 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)

Detaillierte Informationen anzeigen Right Arrow

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The Acute Myeloid Leukemia Diagnostics Market size will be worth USD 6,538.78 million by 2031.
The Acute Myeloid Leukemia Diagnostics Market growth rate is 11.3% during the forecast period.
Increase in Awareness Regarding Leukemia Cancer, Novel Technological Advancements in Leukemia Diagnostics and the Growing Prevalence of Leukemia Cancer are the growth drivers of the Acute Myeloid Leukemia Diagnostics Market.
The product type, test type, cancer type, age group, gender, end user, and distribution channel are the factors on which the Acute Myeloid Leukemia Diagnostics Market research is based.
Major companies in the Acute Myeloid Leukemia Diagnostics Market are CANON MEDICAL SYSTEMS CORPORATION, Sysmex Corporation, Epigenomics AG, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Abbott, QIAGEN, Agilent Technologies, Inc., Siemens Healthcare GmbH, BIOMERIEUX, Exact Sciences Corporation, Merck KGaA, Hologic Inc., DiaSorin S.p.A., Illumina, Inc., Koninklijke Philips N.V., BD, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., FONAR Corp., Time Medical Holding., Sonic Healthcare, PlexBio, MinFound Medical Systems Co., Ltd, Medonica Co. Ltd, Thermo Fisher Scientific Inc., and SternMed GmbH.